Welcome
Support Centre
11 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Control of Rheumatoid Arthritis (RA) by oral tolerance
Source of recordUK Trials
ISRCTNISRCTN98945627
Date ISRCTN assigned18/07/2002
Local reference number(s)S0523
Public titleControl of Rheumatoid Arthritis (RA) by oral tolerance
Scientific title
AcronymN/A
Disease/condition/study domainRheumatoid arthritis
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. RA patients aged over 18 and fulfilling the 1987 American College of Rheumatology (ACR) criteria for the diagnosis of RA were entered into the study after giving their written informed consent
2. Patients must have had the disease at least two years and have failed at least one Slow Acting Anti-Rheumatic Drug (SAARD)
3. All the patients had to have active arthritis defined by the presence of three out of four clinical criteria: three or more swollen joints, six or more tender joints, early morning stiffness over 45 minutes and Erythrocyte Sedimentation Rate (ESR) over 28 mm/h. Oral steroid treatment was permitted if the dose was more than 10 mg/day
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Anticipated start date01/01/1998
Anticipated end date01/01/2000
Status of trialCompleted
Target number of participantsNot provided at time of registration
InterventionsPatients were randomly assigned to receive either 0.05 mg, 0.5 mg or 5 mg daily of bovine type II collagen (CII) or placebo for six months
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
PublicationsResults in http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11592359
Sources of fundingArthritis Research Campaign (UK)
Sponsor nameArthritis Research Campaign (UK)
Sponsor detailsCopeman House
St Mary's Court
St Mary's Gate
Chesterfield
Derbyshire
United Kingdom
S41 7TD
Sponsor emailinfo@arc.org.uk
Sponsor websitehttp://www.arc.org.uk
Contact nameDr Ernest Choy
Contact detailsAcademic Department of Rheumatology
GKT School of Medicines
King's College Hospital (Dulwich)
East Dulwich Grove
London
United Kingdom
SE22 8PT
Contact telephone+44 (0)20 7346 6446
Contact fax+44 (0)20 7346 6475
Contact emailernest.choy@kcl.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN98945627
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central